Skip to Main Content

An official website of the United States government

About this Publication
Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis.
Pubmed ID
25635704 (View this publication on the PubMed website)
J Thorac Imaging. 2015 Jan; Volume [Epub ahead of print]: Pages [Epub ahead of print]
Black WC
  • Department of Radiology, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

The National Lung Screening Trial (NLST) demonstrated that screening with low-dose CT versus chest radiography reduced lung cancer mortality by 16% to 20%. More recently, a cost-effectiveness analysis (CEA) of CT screening for lung cancer versus no screening in the NLST was performed. The CEA conformed to the reference-case recommendations of the US Panel on Cost-Effectiveness in Health and Medicine, including the use of the societal perspective and an annual discount rate of 3%. The CEA was based on several important assumptions. In this paper, I review the methods and assumptions used to obtain the base case estimate of $81,000 per quality-adjusted life-year gained. In addition, I show how this estimate varied widely among different subsets and when some of the base case assumptions were changed and speculate on the cost-effectiveness of CT screening for lung cancer outside the NLST.

Related CDAS Studies
Related CDAS Projects